| scholarly article | Q13442814 |
| P50 | author | Mieczyslaw Litwin | Q57063631 |
| Augustina Jankauskiene | Q101237887 | ||
| Aleksandra Żurowska | Q112571552 | ||
| Rukshana Shroff | Q37830555 | ||
| Giovanni Montini | Q42424275 | ||
| P2093 | author name string | Franz Schaefer | |
| Elke Wühl | |||
| Fatih Ozaltin | |||
| ESCAPE Trial Group | |||
| Antonella Trivelli | |||
| Stefano Picca | |||
| Ali Anarat | |||
| Peter Sallay | |||
| Marina Charbit | |||
| Helen Aitkenhead | |||
| Nikola Costa | |||
| P2860 | cites work | Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. | Q53551859 |
| Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy | Q62933141 | ||
| Urinary and dialysate losses of vitamin D-binding protein in children on chronic peritoneal dialysis | Q63979887 | ||
| Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy | Q79326178 | ||
| Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF- beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial | Q81364032 | ||
| Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial | Q82147201 | ||
| Klotho: an elixir of youth for the vasculature? | Q82920246 | ||
| An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease | Q84199625 | ||
| Vitamin D Deficiency, Inflammation, and Albuminuria in Chronic Kidney Disease: Complex Interactions | Q84981120 | ||
| Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease | Q85015079 | ||
| In chronic kidney disease, serum α-Klotho is related to serum bicarbonate and proteinuria | Q85258646 | ||
| Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency | Q85831183 | ||
| In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage | Q28574231 | ||
| Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists | Q33904463 | ||
| The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis | Q34122611 | ||
| Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | Q34254721 | ||
| Progression, remission, regression of chronic renal diseases | Q34264270 | ||
| Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial | Q34625011 | ||
| 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system | Q34793842 | ||
| Active vitamin D treatment for reduction of residual proteinuria: a systematic review | Q34912750 | ||
| Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy | Q35025432 | ||
| Changes in albuminuria predict mortality and morbidity in patients with vascular disease | Q35108899 | ||
| Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study | Q36091406 | ||
| Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase | Q36924964 | ||
| Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. | Q37280832 | ||
| Vitamin D status and arterial hypertension: a systematic review | Q37581406 | ||
| Can vitamin D slow down the progression of chronic kidney disease? | Q37967396 | ||
| Klotho in health and disease | Q38015713 | ||
| Role of Fosinopril and Valsartan on Klotho Gene Expression Induced by Angiotensin II in Rat Renal Tubular Epithelial Cells | Q39689292 | ||
| Strict blood-pressure control and progression of renal failure in children | Q43257210 | ||
| Retarding progression of chronic renal disease: the neglected issue of residual proteinuria | Q44445107 | ||
| The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study | Q44487823 | ||
| Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. | Q45930492 | ||
| Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium | Q46228251 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? | Q46529781 | ||
| The aggravating mechanisms of aldosterone on kidney fibrosis | Q46542770 | ||
| Antiproteinuric effect of oral paricalcitol in chronic kidney disease | Q46826570 | ||
| Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. | Q51199021 | ||
| 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. | Q51578714 | ||
| Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. | Q52031457 | ||
| Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population. | Q53255656 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 314-322 | |
| P577 | publication date | 2015-06-11 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. | |
| P478 | volume | 27 |
| Q47854753 | Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children |
| Q64053427 | Atypical presentation of familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a patient with a new claudin-16 gene mutation |
| Q37279085 | CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today? |
| Q48032432 | Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. |
| Q38972469 | Extrarenal effects of FGF23. |
| Q41996768 | Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics |
| Q46004871 | Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. |
| Q37695914 | Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review |
| Q42754549 | Mushroom Clouds for Vitamin D? |
| Q55221465 | Paracrine Effects of FGF23 on the Heart. |
| Q39003568 | Potential application of klotho in human chronic kidney disease |
| Q28078020 | Stop chronic kidney disease progression: Time is approaching |
| Q38644586 | The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study |
| Q58106381 | Vitamin D and cardiovascular disease in chronic kidney disease |
| Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.